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Synthetic cannabinoids- (SCs-) induced psychosis is a growing public health concern. It leads to significant impairment, including
emotional distress, difficulty communicating, and other debilitating symptoms. In this case report, we discuss a patient with no
previous history of psychotic symptoms, presenting with first-episode psychosis in the context of progressive, acutely worsening,
disorganized, psychotic thoughts and behaviors following prolonged use of SCs. We also discuss relevant literature on SCs-induced
psychosis, highlighting its prevalence, presentation, diagnosis, and recommended management. It is important to diagnose and treat
SCs-induced psychosis as early and efficiently as possible, in order to alleviate symptoms while limiting functional impairment and
emotional distress to the patient.

1. Introduction
Use of synthetic cannabinoids (SCs) is a growing problem
internationally. Frequency of use may be influenced by multiple factors including a desire to get high while avoiding a positive urine toxicology, the curiosity for trying a new drug, and
the misconception that it is not illegal and therefore it is safe
[1, 2]. One study found that, in the United States, SCs are the
second most frequently used illicit substance after cannabis
[3]. The majority of users are Caucasian, single men, with a
mean age of 26, and adolescents account for 40% of users [2,
4–7]. It appears that groups, such as habitual cannabis users,
university students, dance club attendees, and military personnel, may be the most common users of SCs [5, 6]. Approximately 84–98% of SCs users have been reported to also use
cannabis [2, 5–7]. The most common route of administration

is smoking via cigarettes, blunt, or pipe, but SCs can also be
taken orally, rectally, or via vaporization [2, 7].
It is understood that SCs are often coconsumed as a blend
or combination of a variety of different chemical compounds.
There has been ongoing synthesis and development of new
SCs, with 177 entities reported as new psychoactive substances
to the United Nations Office of Drug and Crime (UNODC)
[8, 9]. Although there are many new analogues created daily,
the majority of SCs can be categorized into seven distinct
structural groups, including naphthoylindoles (e.g., JWH,
including subcompounds JWH-018, JWH-073, and JWH398), naphthylmethylindoles, naphthoylpyrroles, naphthylmethylindenes, phenylacetylindoles (e.g., benzoylindoles,
JWH-250), cyclohexylphenols (e.g., CP 47,497 and homologues of CP 47,497), and classical cannabinoids (e.g., HU-210)
[1, 10, 11]. Most of the ingested synthetic substances contain
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a mixture of 2 or more of these compounds; for example,
K2 or “Spice” and related drugs often contain a mixture of
JWH-018 and CP-47,497 and may also contain other SCs
[7, 10, 11]. Naturally occurring psychoactive plants and herbs,
such as Leonotis leonurus (i.e., wild dagga) and Pedicularis
densiflora (i.e., Indian warrior), are often used as carriers for
the aerosolized synthetic cannabinoids [5, 7, 11].
Synthetic cannabinoids mainly interact with cannabinoid
receptors (CB) [2–5, 7, 10]. One type of CB, CB1 receptors,
is mainly located in the brain and throughout the central
nervous system [3]. The second major type of CB, CB2 receptors, is mainly found in the peripheral nervous system, in the
immune system where they mediate the immunomodulatory
effects of cannabinoids, and only sparsely in the central
nervous system [2]. The role of CB2 receptors in the central
nervous system has yet to be elucidated [2, 12]. Similarly,
SCs’ effects on CB2 receptors are not completely understood.
However, SCs are known to act as high potency, complete
agonists at the CB1 receptor [2, 3, 5, 7, 10]. Thus SCs exert
stronger effects at these receptors relative to tetrahydrocannabinol (THC), which is only a partial agonist [2, 3, 5, 7, 10]. The
effect of SCs on the CB1 receptor has been reported to be five
times greater than that of THC [10].
Symptoms of intoxication following use of SCs often
include paranoia, psychosis (including delusional thoughts
and hallucinations), and severe agitation [1, 5, 7, 13]. Some
of these hallucinations differ from those more common in
endogenous psychosis, with prominent visual changes such as
“flashes of color,” “geometric patterns,” “fractals,” and “trails”
[2]. Other psychiatric symptoms include depersonalization,
dissociation, anxiety, and catatonia [2]. These effects usually
begin within minutes of use and last 2–6 hours, though in
some cases the effects last much longer and can range from
1 week to several months [1–3, 5, 7]. Persistent, delayed psychotomimetic effects of ingestion may resemble the trajectory
and severity of psychotic symptoms seen in conditions such
as schizophrenia [1].
Medical complications following ingestion of SCs can be
neurological (61.9%), cardiovascular (43.5%), gastrointestinal
(21.1%), respiratory (8.0%), ocular (5%), dermal (2.6%), renal
(0.9%), and hematological (0.4%) complications [2]. Common neurological effects include tremor, ataxia, nystagmus,
fasciculations, and hypertonicity. Seizures are less common
but have also been reported [3]. The most common cardiovascular effects are tachycardia and hypertension, though fatal
SCs-induced myocardial infarctions have also been reported
[3]. Gastrointestinal effects include nausea, vomiting, and
increased appetite [3]. Renal effects can include acute kidney
injury, requiring hemodialysis in severe cases [3, 14].
Diagnosis by urine and serum toxicology is difficult
because drug designers frequently change functional groups,
change substitutions, and alter moieties of substances; these
modifications interfere with detection on these screens [5, 7,
15]. Some military grade screens can detect the more common
SCs, but detection is often not possible in a hospital setting;
these limitations may be related to the use of these products
by those wishing to avoid persecution and positive tests
on routine hospital and institution-implemented screenings
[5, 7, 10, 15]. When a detailed history with accompanying
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symptoms leads to strong suspicion, in addition to urine and
serum toxicology, other diagnostic tests such as electrolytes,
CBC, cardiac enzymes, and EKG should be used to detect any
physiological complications that may be present [7, 13].
Treatment often includes supportive measures since no
specific antidote is available [5, 7]. Psychiatric symptoms are
usually managed with monitored observation [5, 7] and psychiatric consultation if symptoms persist. Benzodiazepines
are often used to manage anxiety and agitation, while antipsychotics are second-line agents, as they may potentially lower
seizure threshold (increasing risk, as SCs often lower seizure
threshold) [3, 5, 7]. Long-term treatment options include
substance abuse treatment programs that focus on behavioral
change, individual and group counseling, cognitive behavioral therapy (CBT), and 12-step treatment groups [5, 7].

2. Case Report
Herein we describe an 18-year-old antipsychotic-naı̈ve African American male with no past psychiatric history or hospitalizations, who was admitted after presenting to the psychiatric emergency room (ER) with a first-time psychotic
episode in the context of prolonged synthetic cannabinoid
agonist ingestion via inhalation. This patient “Mr. A” presented after experiencing over 1.5 weeks of insomnia, elated
mood, agitation, paranoid ideation, beliefs that others were
inserting thoughts into his head (“thought insertion”) and
that his thoughts could be read by others (“thought broadcasting”), pacing, bizarre delusional thoughts with thought
derailment, and disorganized behavior.
Collateral from patient’s mother revealed progressive
increase in substance use (particularly cannabinoids via
smoke/inhalation) in the preceding 4 months, paranoid
auditory hallucinations, delusions, insomnia with 0–2 hours
of sleep per night, confusion, decreased short-term memory,
and worsened symptoms in the previous 2 weeks, affecting
his activities of daily living. She reported that 3-4 days before
admission, Mr. A exhibited progressive rigidity, intermittent
mutism, and cognitive slowing. Furthermore, Mr. A’s mother
reported that the day prior to admission, he exhibited acute
confusion, amnesia, and verbalized delusions that his uncle,
with whom he previously had a friendly and close relationship, was trying to kill him and that he would not be able to
stay at his job because people were watching him, trying to
“sell his soul” and “make his arms shorter.” On initial assessment, Mr. A’s thought process was disorganized; he was confused, irritable, and avolitional, displaying mild rigidity, catatonia, and intermittent mutism, reacting to internal stimuli,
mumbling, and frequently providing only simple “yes” or
“no” answers. He adamantly denied any history of suicidal ideation, plan, intent, or self-inflicted physical injuries.
Mr. A appeared hunched over with rigid, flexed, inwardly
rotated extremities; he retained a stiff posture throughout the
encounter. His eyes were initially closed, though he was awake
and responding to painful stimuli. Reflexes were normal in
the upper and lower extremities and there were no signs of
cog-wheeling or clasp-knife rigidity.
His affect was guarded, suspicious, and perplexed with
apparent slowed cognition, thought blocking, and stuttering.
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He appeared to be responding to auditory hallucinations,
which he only vaguely endorsed following repeated questioning during the interview. The patient denied all symptoms
related to mania. There was no prior history of catatonia, dystonia, stiffness, mutism, tic disorder, obsessive-compulsive
disorder, or involuntary movements. Mr. A had no known
drug or environmental allergies. Blood alcohol was negative,
yet the urine toxicology was positive for cannabinoids. Blood
labs, including N-methyl-D-aspartate (NMDA) antibodies,
all were within normal limits as was his head computerized tomography scan. Magnetic resonance imaging, with
sedation for control of agitation, and electroencephalography
were unremarkable.
Social history revealed that Mr. A dropped out of school
in 11th grade due to difficulties concentrating, consistent with
his earlier educational history. This supports reported history
that he did not have any disorientation or acute cognitive
decline from his baseline at that time. In addition, he had
spent time in a correctional facility 2 years prior to admission
after violating a restraining order obtained by his mother
for agitated, violent behaviors, verbal abuse, and physical
abuse, which had not recurred since. There was no known
family psychiatric history, yet knowledge of any psychiatric
illness or substance abuse was limited on his paternal side
because Mr. A had never known his father, who had no
contact with the family since Mr. A’s birth. Mr. A reported
alcohol consumption 1-2 times per week, with an average of
1-2 mixed alcoholic beverages on each use, in social settings.
He reported that, for the previous 3-4 weeks, he had only
been using what he believed to be synthetic cannabinoids—
smoking multiple “joints” and “blunts” with “K2” and “spice”
daily, but previously he had used cannabis as well. He denied
history of recent sexual encounters or any history of sexually
transmitted diseases (STDs).
During the two-week hospital course, Mr. A was treated
with intermittent doses of lorazepam 2 mg orally, as needed,
with significant improvement in stiffness. He was stabilized
over 1.5 weeks on oral risperidone, 2 mg in the morning
and 3 mg at bedtime, with resolution of paranoid ideation,
abnormal thought processes, and stiffness. As the risperidone
was titrated, the need for lorazepam progressively decreased.
When mood was stable, with resolved psychosis and paranoia, Mr. A was discharged and followed as an outpatient. On
the first postdischarge assessment (1 week later), Mr. A was
coherent, with logical thought process, though he displayed
mild bilateral stiffness, stuttering, and gait abnormalities
with short-stepping, along with markedly constricted affect—
all suggestive of mild antipsychotic-induced extrapyramidal
symptoms (EPS). The oral risperidone dose was tapered
to 2 mg twice daily (BID) and oral benztropine 0.5 mg at
bedtime was added with improvement in affect, dystonia, and
continued mood stability. One week later, risperidone was
tapered to 3 mg at bedtime, with continued improvement.
Mr. A was no longer psychotic or disorganized on any
assessments since admission to the outpatient clinic, and the
dystonia, EPS, and stiffness were markedly improving.
At the next appointment, 2 weeks after discharge, Mr.
A presented with recurrence of catatonia, stiffness, mutism,
auditory hallucinations, disorganized speech and thought
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process, and blunted affect. He confirmed that he had
relapsed to using SCs and reported noncompliance with his
risperidone for the last 4 days. Mr. A again exhibited pacing, along with bizarre behavior and delusions, stating that
“security guards” at the vocational job location could read his
thoughts and were tracking him. This acute worsening led to
rehospitalization for stabilization and management. On hospitalization, with discontinuation of SCs use and reinitiation
of risperidone, symptoms again improved drastically, and
risperidone was tapered to 2 mg BID. Mr. A was again
discharged for further follow-up, including a partial hospitalization program at a combined substance abuse and
psychiatric treatment (“dual-diagnosis”) center with daily
activities and structured treatment. Mr. A continued to do
well on this regimen.

3. Discussion
Our patient experienced a first-episode of psychosis related
to use of SCs, with disorganized and paranoid thought
processes. Similar symptoms have been reported in many
patients with preexisting psychotic conditions after ingestion
of SCs [16]. Additionally, cases of first-episode psychosis
have been reported in the context of acute and prolonged
ingestion of SCs [2]. Cases reported include a young student
experiencing anxiety, paranoia, and visual and auditory
hallucinations after use of SCs for three weeks [17] and a
36-year-old male that exhibited odd behavior and irritability
for two weeks after using SCs for four consecutive weeks.
His symptoms resolved when he stopped using SCs [18].
One case-series included 10 male subjects, aged 21 through
25, without prior psychiatric history (though 1 had a family
history of psychosis), who developed psychotic symptoms
after prolonged use of SCs and were hospitalized on a
psychiatric unit [16]. These patients’ symptoms included
paranoia, thought disorders, and suicidal ideation [16]. In
this case-series, 7 of the 10 patients received antipsychotic
treatment, and hospitalizations ranged from 6 to 10 days. In 7
of the patients, psychosis resolved between 5 and 8 days after
admission, while 3 patients had psychosis that lasted for more
than 5 months [16]. Symptoms including a distinct period
of intermittent, stuporous appearance were common, along
with odd or flat affect, thought blocking, disorganized speech
and behavior, auditory hallucinations, visual hallucinations,
paranoid delusions, and alogia [16]. Suicidal ideation and
insomnia were also reported [16]. As discussed above, the fact
that SCs are often mixed with other psychoactive drugs of
abuse, including cannabis, can complicate or confound the
diagnosis of SCs-related psychosis. Our case is particularly
notable for strong response to antipsychotic medication,
subsequent relapse of psychotic symptoms following relapse
in use of SCs, and repeated response to a second round of
antipsychotic medication treatment.
Various studies have suggested that use of SCs may be
associated with development of psychotic symptoms [10, 16,
19, 20]. Whether many patients who develop first-episode
psychosis after ingestion of SCs have an underlying predisposition to psychosis [1, 21] warrants further investigation.
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In our case, psychosis due to ingestion of SCs was
diagnosed efficiently, which facilitated successful treatment,
beginning with lorazepam administration for catatonic
symptoms and with risperidone to target psychotic symptoms. The strong response to risperidone both as an initial
treatment and following relapse provides additional information indicating that clinicians can use a previously effective
antipsychotic for relapse of SCs-induced psychosis.
Clinicians should be aware of the possibility of cannabinoid-induced psychotic delusions, paranoia, and distorted
thoughts after recent ingestion of SCs, in order to optimally
identify and treat this condition. Treatment may be most
effective when including inpatient admission, maintaining a
substance-free period, and medications for psychosis.
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